Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Classical Hodgkin Lymphoma
Interventions
DRUG

Tislelizumab

200 mg administered via intravenous (IV) infusion once every 3 weeks

DRUG

Salvage Chemotherapy

Salvage chemotherapy administered as assessed as appropriate by the investigator in accordance with the local guideline, including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE (dexamethasone, ifosfamide, carboplatin, etoposide), ICE (ifosfamide, carboplatin, etoposide), IGEV (ifosfamide, gemcitabine, vinorelbine, prednisone), GVD (gemcitabine, vinorelbine, liposomal doxorubicin), and MINE (etoposide, ifosfamide, mesna, mitoxantrone)

Trial Locations (7)

100142

Beijing Cancer Hospital, Beijing

130021

Jilin Cancer Hospital, Changchun

150000

Harbin Medical University Cancer Hospital, Harbin

310022

Zhejiang Cancer Hospital, Hangzhou

362000

Quanzhou First Affliated Hospital of Fujian Medical University, Quanzhou

410013

Hunan Cancer Hospital, Changsha

450000

Henan Cancer Hospital, Zhengzhou

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BeiGene

INDUSTRY

NCT04486391 - Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter